



# Cerebrovascular manifestations of Covid- 19

DR.HODA NAGHSHINEH  
MD,NEUROLOGIST

# Covid-19

- ▶ A novel coronavirus
- ▶ Resembling SARS-Co in many ways, specially they shared the same receptor, angio-tension converting enzyme-2
- ▶ Typical manifestations: fever, cough, diarrhea, fatigue
- ▶ Neurological manifestations: (36.4%)
  - 1.CNS( dizziness, headache, impaired consciousness, acute cerebrovascular disease, ataxia, seizure)
  - 2.PNS (taste/smell impairment, vision impairment, nerve pain)
  - 3.Skeletal muscular injury

# Pathophysiology

## Neuroinvasion and neurovirulence

- ▶ Access may be achieved via two main routes: hematogenous or transneuronal through the olfactory bulb
- ▶ hematogenous route involves directly infecting the blood–brain barrier (BBB) or access via a Trojan such as leukocytes

## ACE2 receptor and angiotensin (1-7) (ANG (1-7))

- ▶ ACE2 is a carboxypeptidase that converts angiotensin I into ANG (1-7), which is an essential component of the renin-angiotensin system
- ▶ ANG (1-7) : synthesized in endothelial cells and has a downstream effect stimulates the release of prostaglandin and nitric oxide, enhances the metabolic actions of brady kinin, and inhibits smooth muscle cell growth
- ▶ binding of SARSCoV-2 to the ACE2 receptor may inhibit its downstream effect via pathway down regulation or cell lysis, ultimately decreasing ANG (1-7) synthesis counteract neuroprotective properties and blood pressure auto-regulation (increase in sympathetic activity)

## Hypercoagulable state

- ▶ hypercoagulable state caused by the virus-induced cytokine storm
- ▶ critically ill COVID-19 patients had increased proinflammatory cytokines, including IL-2 and TNF- $\alpha$ , which can up-regulate the coagulation system.
- ▶ In a recent Dutch study, there was a 31% incidence of thrombotic complications in patients with COVID-19 admitted to the ICU, mainly consisting of acute pulmonary embolism, deep vein thrombosis, ischemic stroke, myocardial infarction, and systemic arterial embolism

# Features of Covid-19 associated ischemic stroke

- ▶ large vessel occlusion
- ▶ multiterritory infarcts
- ▶ Venous thromboembolism
- ▶ raised inflammatory markers
- ▶ antiphospholipid antibody production
- ▶ a younger age of presentation
- ▶ concurrent severe systemic inflammation with organ failure
- ▶ reported incidence of stroke in COVID-19 hospitalized patients is 0.9–2%, with an increased incidence in the young

# Features of Covid-19 associated hemorrhagic stroke

- ▶ Relatively young with a mean age of 52.2 years (range 41 – 64 years with morbidity mortality generally increases with advancing age)
- ▶ lobar predominance (Lobar ICH occurs in 15 – 30% of conventional cases, and is predominantly associated with an underlying vascular abnormality)
- ▶ having evidence of a period of prolonged inflammation, as demonstrated firstly by markedly raised D-Dimer values and secondly by severe end organ damage

# Risk factors for ischemic stroke

- ▶ Older age
- ▶ Black
- ▶ Higher frequency of HTN
- ▶ Diabetes
- ▶ Hyperlipidemia
- ▶ Arterial fibrillation
- ▶ Congestive heart failure
- ▶ Organ failure
- ▶ More severe symptoms, less response to TPA



# Risk factors for intra-cerebral hemorrhage

- ▶ Older age
- ▶ Caucasian race
- ▶ Respiratory failure requiring mechanical ventilation
- ▶ Anticoagulation

# Take home message

- ▶ Clinicians should have a low threshold for suspicion and investigation particularly those younger individuals receiving organ support beyond two weeks of their COVID-19 illness, who are also being treated with anticoagulants
- ▶ Acute ischemic stroke patients with suspected COVID-19 have to be evaluated under the assumption that they have COVID-19

THANK YOU FOR  
YOUR ATTENTION

